Valeant Pharmaceuticals (NYSE: VRX) and Gilead Sciences (NASDAQ: GILD) are in the bargain bin, but first quarter financial results show that sales continue to decline at both companies. Are these companies making enough progress to make them worth owning in portfolios?In this episode of the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell search Valeant Pharmaceuticals and Gilead Sciences first-quarter financials for clues to determine if now is a good time to buy.Thanks to Slack for supporting Motley Fool.